Elise Marie Wilson

Dr. Elise Marie Wilson

Moores Cancer Center, University of California San Diego Medical Center, San Diego, California, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EWElise Marie Wilson
Elise Marie Wilson
RERamez N. Eskander
Ramez N. Eskander
PBPratibha S. Binder
Pratibha S. Binder
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors mutate and progress through traditional lines of treatment, new therapies must be developed to overcome resistance and target cancer-specific receptors and mutations. Recent advances in the development of immunotherapy and antibody–drug conjugates have resulted in compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers. In the last decade, several immunotherapy agents have received FDA approval or NCCN guideline recommendation for the treatment of gynecologic malignancies, including dostarlimab for advanced or recurrent endometrial cancer and pembrolizumab for advanced or recurrent cervical and endometrial cancers. Several other immunotherapeutic agents are under active investigation. Development of antibody–drug conjugates including tisotumab vedotin in cervical cancer, mirvetuximab soravtansine in ovarian cancer, and trastuzumab deruxtecan in multiple gynecologic cancers has translated into exciting efficacy signals, prompting full drug approvals and additional investigation. This article aims to review recent novel advances in targeted treatments for gynecologic malignancies, highlighting the trials and data underlying these novel interventions.

1 September 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
AZAbigail S. Zamorano
Abigail S. Zamorano
EWElise Marie Wilson
Elise Marie Wilson
JLJingxia Liu
Jingxia Liu
ALAndrea Leon
Andrea Leon
LKLindsay M. Kuroki
Lindsay M. Kuroki
AHAndrea R. Hagemann
Andrea R. Hagemann

17 October 2024 in Cancer
Verified
Journal Article
Closed access
EWElise Marie Wilson
Elise Marie Wilson
RHRuizhi Huang
Ruizhi Huang
KJKristen D. Jones
Kristen D. Jones
IHIan Hagemann
Ian Hagemann
STSarah Temkin
Sarah Temkin
AHAndrea R. Hagemann
Andrea R. Hagemann

29 August 2025 in Science Advances
Verified
Journal Article
Open access
JSJeremy Shek
Jeremy Shek
CSChen Sun
Chen Sun
EWElise Marie Wilson
Elise Marie Wilson
FMFatemeh Moadab
Fatemeh Moadab
KHKathryn M. Hastie
Kathryn M. Hastie
ESErica Ollmann Saphire
Erica Ollmann Saphire
Human endogenous retroviruses (HERVs) are remnants of ancient infections that comprise ~8% of the human genome. The HERV-K envelope glycoprotein (Env) is aberrantly expressed in cancers, autoimmune disorders, and neurodegenerative diseases, and is targeted by patients’ own antibodies. However, a lack of structural information has limited molecular and immunological studies of the roles of HERVs in disease. Here, we present cryo–electron microscopy structures of stabilized HERV-K Env in the prefusion conformation, revealing a distinct fold and architecture compared to HIV and simian immunodeficiency virus. We also generated and characterized a panel of monoclonal antibodies with subunit and conformational specificity, serving as valuable research tools. These antibodies enabled structure determination of the postfusion conformation of HERV-K Env, including its unique “tether” helix, and antibody-bound prefusion Env. Together, these results provide a structural framework that opens the door to mechanistic studies of HERV-K Env and tools for its evaluation as a potential therapeutic target.

29 November 2025 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
JTJo’AN Tankou
Jo’AN Tankou
LPLisa M. Pollack
Lisa M. Pollack
EWElise Marie Wilson
Elise Marie Wilson
IKIris Kuo
Iris Kuo
MWMei Wang
Mei Wang
AHAndrea R. Hagemann
Andrea R. Hagemann